pharma news, views and analysis

in News
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody
August 3, 2020 Share
X
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody
https://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
in News
Roche’s NTRK tumour-agnostic therapy Rozlytrek approved in Europe
August 3, 2020 Share
X
Roche’s NTRK tumour-agnostic therapy Rozlytrek approved in Europe
https://pharmaphorum.com/news/roches-tumour-agnostic-therapy-approved-in-europe/

Latest News

Regeneron pairs with BioNTech on melanoma immunotherapy

Regeneron and Sanofi’s PD-1 inhibitor Libtayo will be tested in tandem with a cancer vaccine developed by BioNTech

Regeneron pairs with BioNTech on melanoma immunotherapy

https://pharmaphorum.com/news/regeneron-pairs-with-biontech-on-melanoma-immunotherapy/

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma –

Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge

https://pharmaphorum.com/news/roches-tecentriq-claims-melanoma-ok-but-dont-expect-a-sales-surge/

BMS ‘bet’ with Celgene shareholders in balance after CAR-T refile

Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a

BMS ‘bet’ with Celgene shareholders in balance after CAR-T refile

https://pharmaphorum.com/news/bms-2/

See all

Views & analysis

GSK’s John Fleming on rethinking oncology from the ground up

What if we could look at cancer treatment from a completely fresh perspective? This is the philosophy GSK’s

GSK’s John Fleming on rethinking oncology from the ground up

https://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/gsks-john-fleming-on-rethinking-oncology-from-the-ground-up/

Commercialising innovative new medicines

As pharmaceutical ingenuity hits new heights, ensuring that patients gain access to innovative medicines requires a unique combination

Commercialising innovative new medicines

https://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/commercialising-innovative-new-medicines/

How to increase haematologists’ and oncologists’ confidence with new treatments

A new whitepaper from Medscape highlights the difficulties haematologists and oncologists face in keeping up with rapid developments

How to increase haematologists’ and oncologists’ confidence with new treatments

https://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/how-to-increase-haematologists-and-oncologists-confidence-with-new-treatments/

See all

Debates & Insights

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

See all

Partner Content

Q&A with SKAN AG speaker released for HPAPI 2020

HPAPI Speaker Interview

Q&A with SKAN AG speaker released for HPAPI 2020

https://pharmaphorum.com/partner-content/qa-with-skan-ag-speaker-released-forhpapi-2020/

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

RNA Therapeutics

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/attendee-list-released-for-smis-9th-annual-rna-therapeutics/

RNA Therapeutics conference will take place in just 4 weeks!

4 Weeks Until RNA Therapeutics

RNA Therapeutics conference will take place in just 4 weeks!

https://pharmaphorum.com/partner-content-oncology/rna-therapeutics-conference-will-take-place-in-just-4-weeks/

See all

Search

Advanced Search

Trending